Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Aro Biotherapeutics is raising $90,337,478.00 in new funding. Sources indicate as part of senior management Chief Administrative Officer, Mark Laurenzi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aro Biotherapeutics

Unlocking the Potential of Genetic Medicines. Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. At Aro, we’re developing a patented platform technology called Centyrins that are uniquely positioned to achieve precise targeting of diverse therapeutic payloads to specific cells of interest. Our initial efforts are focused on discovering and developing Centyrin-oligonucleotide conjugate therapies that are meant to address one of the greatest challenges facing oligonucleotide-based medicines today: targeted delivery of oligonucleotides to extra-hepatic tissues.

To learn more about Aro Biotherapeutics, visit http://www.arobiotx.com/

Contact:
Mark Laurenzi, Chief Administrative Officer
215-544-1175
mlaurenzi@arobiotx.com
https://www.linkedin.com/in/mark-laurenzi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved